SAN JOSE, Calif. June 17, 2024 In a significant stride towards revolutionizing urological care, PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a pioneering surgical robotics company, proudly announced today that the American Medical Association (AMA) has established a new Current Procedural Terminology (CPT) Category I code for its groundbreaking Aquablation therapy. This new code is a testament to Aquablation therapy’s impact and clinical efficacy in treating benign prostatic hyperplasia (BPH), a prevalent and often debilitating condition among older men.
Unveiling the Next Generation in Urological Care
PROCEPT BioRobotics has been at the forefront of developing transformative solutions in urology, with Aquablation therapy representing a fusion of sophisticated robotics and advanced imaging. This innovative procedure leverages the precision of a high-velocity waterjet to remove excess prostate tissue safely and effectively. The non-thermal, water-based technology contrasts sharply with traditional surgical methods, mitigating the risks associated with heat-based procedures such as transurethral resection of the prostate (TURP) and laser therapies.
Clinical Validation and Broad Acceptance
The newly assigned CPT Category I code, a universally recognized identifier used by healthcare professionals for procedural reporting and insurance claims, underscores the clinical validation and broad acceptance Aquablation therapy has garnered. In recent clinical trials, Aquablation therapy has demonstrated significant advantages, including reduced surgical times, minimal intraoperative bleeding, and expedited recovery periods, compared to conventional BPH treatments.
This CPT Category I code is a monumental achievement not just for PROCEPT BioRobotics but for the entire field of urology. It affirms the robust clinical outcomes Aquablation therapy consistently delivers and facilitates broader access to this much-needed treatment for patients suffering from BPH, said Reza Zadno, CEO of PROCEPT BioRobotics. This milestone marks a pivotal point in our mission to advance patient care by providing innovative and efficacious therapeutic solutions.
Addressing a Pervasive Condition
Benign prostatic hyperplasia is a common condition affecting millions of men globally. Characterized by the non-cancerous enlargement of the prostate gland, BPH can lead to uncomfortable and potentially severe urinary symptoms, including frequency, urgency, nocturia, and weak urine flow. Traditional surgical interventions for BPH, while effective, often come with significant side effects and extended recovery times, making the advent of Aquablation therapy particularly noteworthy.
Implications for the Medical Community
The establishment of a CPT Category I code for Aquablation therapy holds far-reaching implications for the medical community. It simplifies the billing process and enables seamless integration into clinical practice, fostering greater adoption among urologists and healthcare providers. Moreover, with the standardized coding, insurance providers are more likely to offer coverage, removing financial barriers and making the therapy accessible to a broader patient base.
Looking Ahead
As PROCEPT BioRobotics continues to innovate and expand its portfolio, the attention will be on harnessing cutting-edge technology to address other pressing medical conditions. The company’s commitment to enhancing patient outcomes through minimally invasive robotic procedures signals a future where complex surgeries become safer, faster, and more effective.
In summary, the AMA’s recognition of Aquablation therapy via the new CPT Category I code is more than just an administrative update; it is an acknowledgment of the therapy’s clinical viability and the promise it holds for transforming urological care. As PROCEPT BioRobotics charts the course ahead, this milestone stands as a beacon of progress and a harbinger of continued innovation in the medical field.’
Comments